> Details

Lipka, Daniel B.; Witte, Tania; Toth, Reka; Yang, Jing; Wiesenfarth, Manuel; Nöllke, Peter; Fischer, Alexandra; Brocks, David; Gu, Zuguang; Park, Jeongbin; Strahm, Brigitte; Wlodarski, Marcin; Yoshimi, Ayami; Claus, Rainer; Lübbert, Michael; Busch, Hauke; Boerries, Melanie; Hartmann, Mark; Schönung, Maximilian; Kilik, Umut; Langstein, Jens; Wierzbinska, Justyna A.; Pabst, Caroline; Garg, Swati; [...]

RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia
  • Contributor: Lipka, Daniel B.; Witte, Tania; Toth, Reka; Yang, Jing; Wiesenfarth, Manuel; Nöllke, Peter; Fischer, Alexandra; Brocks, David; Gu, Zuguang; Park, Jeongbin; Strahm, Brigitte; Wlodarski, Marcin; Yoshimi, Ayami; Claus, Rainer; Lübbert, Michael; Busch, Hauke; Boerries, Melanie; Hartmann, Mark; Schönung, Maximilian; Kilik, Umut; Langstein, Jens; Wierzbinska, Justyna A.; Pabst, Caroline; Garg, Swati; [...]
  • imprint: Springer Science and Business Media LLC, 2017
  • Published in: Nature Communications
  • Language: English
  • DOI: 10.1038/s41467-017-02177-w
  • ISSN: 2041-1723
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:p>Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative disorder of early childhood characterized by mutations activating RAS signaling. Established clinical and genetic markers fail to fully recapitulate the clinical and biological heterogeneity of this disease. Here we report DNA methylome analysis and mutation profiling of 167 JMML samples. We identify three JMML subgroups with unique molecular and clinical characteristics. The high methylation group (HM) is characterized by somatic <jats:italic>PTPN11</jats:italic> mutations and poor clinical outcome. The low methylation group is enriched for somatic <jats:italic>NRAS</jats:italic> and <jats:italic>CBL</jats:italic> mutations, as well as for Noonan patients, and has a good prognosis. The intermediate methylation group (IM) shows enrichment for monosomy 7 and somatic <jats:italic>KRAS</jats:italic> mutations. Hypermethylation is associated with repressed chromatin, genes regulated by RAS signaling, frequent co-occurrence of RAS pathway mutations and upregulation of <jats:italic>DNMT1</jats:italic> and <jats:italic>DNMT3B</jats:italic>, suggesting a link between activation of the DNA methylation machinery and mutational patterns in JMML.</jats:p>
  • Access State: Open Access